Citing Crypto.News, Nasdaq-listed biotech firm Propanc Biopharma has secured up to $100 million in a securities purchase deal with family office Hexstone Capital. The funding will support Propanc’s digital asset strategy, which includes acquiring undervalued Digital Asset Treasury (DAT) companies. The company has already received an initial $1 million, with up to $99 million available over the next year. Propanc plans to use the capital to expand its crypto portfolio and advance its cancer research. The firm aims to identify DATs trading below their intrinsic value to build a diversified digital asset base while continuing to develop its oncology pipeline.
Biotech Firm Propanc Secures $100M for Digital Asset Acquisition
OdailyShare
Source:Show original
Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information.
Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.